Evidence map›Paper›PMID 25689051›Full record

ArticlePloS one2015

Beryllium increases the CD14(dim)CD16+ subset in the lung of chronic beryllium disease.

Li Li, Nabeel Hamzeh, May Gillespie, Jill Elliott, Jieru Wang, Eva Brigitte Gottschall, Peggy M Mroz, Lisa A Maier

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Li LiDepartment of Medicine, National Jewish Health, Denver, Colorado, United States of America; Division of Pulmonary and Critical Care Sciences, Department of Medicine, School of Medicine, Denver, Colorado, United States of America.
Nabeel HamzehDepartment of Medicine, National Jewish Health, Denver, Colorado, United States of America; Division of Pulmonary and Critical Care Sciences, Department of Medicine, School of Medicine, Denver, Colorado, United States of America.
May GillespieDepartment of Medicine, National Jewish Health, Denver, Colorado, United States of America.
Jill ElliottDepartment of Medicine, National Jewish Health, Denver, Colorado, United States of America.
Jieru WangDepartment of Pediatrics, Division of Pulmonary Medicine, Allergy and Immunology, Children's Hospital of Pittsburgh of University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.
Eva Brigitte GottschallDepartment of Medicine, National Jewish Health, Denver, Colorado, United States of America; Division of Pulmonary and Critical Care Sciences, Department of Medicine, School of Medicine, Denver, Colorado, United States of America; Environmental Occupational Health Department, Colorado School of Public Health, University of Colorado, Denver, Colorado, United States of America.
Peggy M MrozDepartment of Medicine, National Jewish Health, Denver, Colorado, United States of America.
Lisa A MaierDepartment of Medicine, National Jewish Health, Denver, Colorado, United States of America; Division of Pulmonary and Critical Care Sciences, Department of Medicine, School of Medicine, Denver, Colorado, United States of America; Environmental Occupational Health Department, Colorado School of Public Health, University of Colorado, Denver, Colorado, United States of America.
University of Colorado Denver · USNational Jewish Health · USChildren's Hospital of Pittsburgh · USColorado School of Public Health · US

Funding

Colorado Clinical and Translational Sciences InstituteUL1TR001082 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$48.0M
Colorado Clinical and Translational Science Institute (UL1)UL1TR000154 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2012 to 2013
$20.4M
T Cells in Beryllium Sensitization and DiseaseP01ES011810 · NIEHS · UNIVERSITY OF COLORADO DENVER · PI FONTENOT, ANDREW P. · 2002 to 2013
$14.0M
Colorado Career Development Program in the Genetics and Genomics of Lung DiseasesK12HL090147 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI GERACI, MARK W · 2007 to 2012
$2.0M
Regulation of alveolar epithelial homeostasis in acute lung injuryR01HL113655 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WANG, JIERU · 2012 to 2016
$1.9M
Functional Genomics Approach to the Role of the JAK/STAT and MAPK Pathway in CBDK01ES020857 · NIEHS · UNIVERSITY OF COLORADO DENVER · PI LI, LI · 2011 to 2013
$382k
IFN-lambda polymorphisms and host response to respiratory viral infections in humR03AI101953 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WANG, JIERU · 2012 to 2013
$159k
NCATS NIH HHS UL1 TR000154NCATS NIH HHS UL1 TR001082NHLBI NIH HHS K12 HL090147NHLBI NIH HHS K12 HL090147-01NHLBI NIH HHS R01 HL113655NIAID NIH HHS R03 AI101953NIEHS NIH HHS K01 ES020857NIEHS NIH HHS K01ES020857-01NIEHS NIH HHS P01 ES011810NIEHS NIH HHS P01ES11810-06A1
6 · The paper itself

Abstract

CD14dimCD16+ and CD14brightCD16+ cells, which compose a minor population of monocytes in human peripheral blood mononuclear cells (PBMC), have been implicated in several inflammatory diseases. The aim of this study was to investigate whether this phenotype was present as a subset of lung infiltrative alveolar macrophages (AMs) in the granulomatous lung disease, chronic beryllium disease (CBD). The monocytes subsets was determined from PBMC cells and bronchoalveolar lavage (BAL) cells from CBD, beryllium sensitized Non-smoker (BeS-NS) and healthy subjects (HS) using flow cytometry. The impact of smoking on the AMs cell phenotype was determined by using BAL cells from BeS smokers (BeS-S). In comparison with the other monocyte subpopulations, CD14dimCD16+ cells were at decreased frequency in PBMCs of both BeS-NS and CBD and showed higher HLA-DR expression, compared to HS. The AMs from CBD and BeS-NS demonstrated a CD14dimCD16+phenotype, while CD14brightCD16+ cells were found at increased frequency in AMs of BeS, compared to HS. Fresh AMs from BeS-NS and CBD demonstrated significantly greater CD16, CD40, CD86 and HLA-DR than HS and BeS-S. The expression of CD16 on AMs from both CBD and BeS-NS was downregulated significantly after 10μM BeSO4 stimulation. The phagocytic activity of AMs decreased after 10μM BeSO4 treatment in both BeS-NS and CBD, although was altered or reduced in HS and BeS-S. These results suggest that Be increases the CD14dimCD16+ subsets in the lung of CBD subjects. We speculate that Be-stimulates the compartmentalization of a more mature CD16+ macrophage phenotype and that in turn these macrophages are a source of Th1 cytokines and chemokines that perpetuate the Be immune response in CBD. The protective effect of cigarette smoking in BeS-S may be due to the low expression of co-stimulatory markers on AMs from smokers as well as the decreased phagocytic function.

Indexed as

AgedBerylliosisBerylliumBronchoalveolar Lavage FluidChemokinesChronic DiseaseCytokinesFemaleHLA-DR AntigensHumansLeukocytes, MononuclearLipopolysaccharide ReceptorsLungMacrophages, AlveolarMaleMiddle AgedBerylliumberyllium sulfateChemokinesCytokinesHLA-DR AntigensLipopolysaccharide ReceptorsReceptors, IgG

Identifiers

PMID25689051
PMCPMC4331542
OpenAlexW2020967584

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.